Results 41 to 50 of about 3,233 (250)

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach, Sandra Donkervoort, Carola Hedberg‐Oldfors, Giovanni Baranello, Dimah Saade, Precilla D'Souza, Ruchee Patel, Eva Michael, A. Reghan Foley, Diana Bharucha‐Goebel, S. Jin Haugland, Meghan McAnally, Omer Abdul Hamid, Katherine Chao, Ellen F. Macnamara, Alan H. Beggs, Anna Sarkozy, Juliane Mueller, Steven A. Moore, Richard S. Finkel, Cynthia J. Tifft, Francesco Muntoni, Anders Oldfors, Carsten G. Bönnemann   +23 more
wiley   +1 more source

Neuromuscular Weakness and Paralysis Produced by Snakebite Envenoming: Mechanisms and Proposed Standards for Clinical Assessment

Toxins, 2023
Respiratory and airway-protective muscle weakness caused by the blockade of neuromuscular transmission is a major cause of early mortality from snakebite envenoming (SBE).
Philip E. Bickler, Michael Abouyannis, Ashish Bhalla, Matthew R. Lewin   +3 more
doaj   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

Steroidal neuromuscular blocking agents

, 1998
Since 1964 approximately 20 steroidal neuromuscular blocking agents have been evaluated clinically. Pancuronium, a bisquaternary compound designed on the drawingboard, was the first steroidal relaxant introduced into clinical practice worldwide in the ...
Toyooka, H, Shingu, K, Ohmura, A, Hatano, Y, Wierda, JMKH, Mori, K, Fukuda, K   +6 more
core   +2 more sources

Neuromuscular blocking agents and reversal agents

, 2005
The neuromuscular blocking agents in routine clinical use may be classed as depolarizing or nondepolarizing. Suxamethonium is the only example of the depolarizing group and is an agonist at the neuromuscular receptor.
Pollard, Brian J.
core   +1 more source

Neuromuscular Blocking Agents

Journal of Pharmacy and Pharmacology, 1958
Abstract The preparation of two further NSN-tris-ethonium compounds, 9-ethyl-9-thioniaheptadecylenebis(triethylammonium) triiodide (dioctasulphonium triethiodide; DOSE) and 11-ethyl-11-thioniaheneicosylenebis(triethylammonium) triiodide (didecasulphonium triethiodide; DDSE) is described.
D Edwards, J J Lewis, J B Stenlake, M S Zoha   +3 more
openaire   +2 more sources

Comparison of the Effects of Sugammadex Recommended Dose (2 mg/kg) and Fixed Dose of 200 mg on the Reversal of Moderate Neuromuscular Block and Recovery Profile in Adult Patients

Medicina
Background and Objectives: Neuromuscular blocking agents are essential to ensure optimal surgical conditions during general anesthesia. Sugammadex, a selective binding agent, is widely used to reverse neuromuscular blockade.
Ji-Yoon Jung, Sung-Ae Cho, Woojin Kwon, Hongwook Kim, Tae-Yun Sung   +4 more
doaj   +1 more source

Neuromuscular blockade management for intraoperative neural monitoring

Kaohsiung Journal of Medical Sciences, 2020
This article reviews the literature on development of neuromuscular blockade management in thyroid surgery with intraoperative neural monitoring (IONM) in the past decade.
I‐Cheng Lu, Sheng‐Hua Wu, Che‐Wei Wu   +2 more
doaj   +1 more source

Efeitos adversos dos bloqueadores neuromusculares. [PDF]

, 2005
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Maegawa, Beatriz Maciel
core